Novabay Pharmaceuticals Inc RSI
¿Qué es el RSI de Novabay Pharmaceuticals Inc?
El RSI de Novabay Pharmaceuticals Inc es 40.42
¿Cuál es la definición de RSI?
El índice de fortaleza relativa (RSI 14) es un indicador de impulso que compara la magnitud de las ganancias y pérdidas durante un período de tiempo específico para medir la velocidad y el cambio de los movimientos de precios de un valor.
It is used to identify overbought or oversold conditions in the trading of an asset. It oscillates between 0 and 100 and a stock is considered overbought when the RSI is above 70 and oversold when below 30. The relative strength index (RSI) is typically used on a 14-day timeframe and is calculated according to the formula 100 - [ 100 / (1 + RS)] where RS is the ratio of average gain to average loss. In the calculation of average gain and loss for a certain period, taking the prior value plus the current value is a smoothing technique similar to that used in calculating an exponential moving average. This also means that RSI values become more accurate as the calculation period extends.
Sudden large price movements can create false buy or sell signals in the RSI. The RSI is often used in conjunction with trend lines, as trend line support or resistance often coincides with support or resistance levels in the RSI reading. Watching for divergence between price and the RSI indicator is another means of refining its application. Divergence occurs when a security makes a new high or low in price but the RSI does not make a corresponding new high or low value. Bearish divergence, when price makes a new high but the RSI does not is taken as a sell signal. Bullish divergence that is interpreted as a buy signal occurs when price makes a new low, but the RSI value does not.
RSI de compañías en Sector Health Care en NYSEMKT en comparadas con Novabay Pharmaceuticals Inc
¿Qué hace Novabay Pharmaceuticals Inc?
novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across
Empresas con rsi similar a Novabay Pharmaceuticals Inc
- Ad4 Capital Corp tiene RSI de 40.41
- Discovery Communications tiene RSI de 40.41
- Virat Crane Industries tiene RSI de 40.41
- Alexco Resource Corp tiene RSI de 40.41
- CryoPort Inc tiene RSI de 40.41
- Skyworks Solutions tiene RSI de 40.41
- Novabay Pharmaceuticals Inc tiene RSI de 40.42
- G-Resources tiene RSI de 40.43
- Dicks Sporting Goods tiene RSI de 40.43
- Hexcel tiene RSI de 40.43
- Strabag SE tiene RSI de 40.43
- Ling Yui tiene RSI de 40.44
- Gibb River Diamonds tiene RSI de 40.44